517O Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial

Autor:	P. DiSilvestro, S. Banerjee, N. Colombo, G. Scambia, B-G. Kim, A. Oaknin, M.L. Friedlander, A.S. Lisyanskaya, A. Floquet, A. Leary, G.S. Sonke, C. Gourley, A.M. Oza, A.J. Gonzalez Martin, C. Aghajanian, W.H. Bradley, C. Mathews, J. McNamara, E. Lowe, K.N. Moore
Rok vydání:	2022
Předmět:	Oncology Hematology
Zdroj:	Annals of Oncology. 33:S779
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e4e763ac450507334d853ec3a8cd8db2 https://doi.org/10.1016/j.annonc.2022.07.645 Zobrazit plný text záznamu